Prime Medicine (PRME) Return on Invested Capital (2022 - 2025)

Prime Medicine has reported Return on Invested Capital for 4 years, with the latest figure at 0.02% in Q1 2025.

• For the quarter ending Q1 2025, Return on Invested Capital changed 0.0% year-over-year to 0.02%; the trailing twelve-month figure through Mar 2025 stood at 0.02% (changed 0.0% YoY), and the FY2023 full-year result was 0.01%, up 1.0% from the prior year.
• Return on Invested Capital for Q1 2025 stood at 0.02%, down from 0.01% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.01% in Q3 2022, with the low at 0.02% in Q4 2022.
• Historically, Return on Invested Capital has averaged 0.01% across 4 years, with a median of 0.01% in 2023.
• The largest YoY upside for Return on Invested Capital was 1 bps in 2023 against a maximum downside of 1 bps in 2023.
• Prime Medicine's Return on Invested Capital stood at 0.02% in 2022, then jumped by 50 bps to 0.01% in 2023, then rose by 19 bps to 0.01% in 2024, then slumped by 56 bps to 0.02% in 2025.
• The last three Return on Invested Capital figures came in at 0.02% (Q1 2025), 0.01% (Q2 2024), and 0.01% (Q1 2024), per Business Quant data.